|
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We subsequently studied to what extent CPON might affect seizure susceptibility and memory performance, respectively, to address two important questions to evaluate the potential of NPY gene therapy in epilepsy.
|
30367522 |
2019 |
|
Epilepsy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hippocampal neuropeptide Y protein expression following controlled cortical impact and posttraumatic epilepsy.
|
30146352 |
2018 |
|
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
This first demonstration that an AAV-NPY construct can successfully transduce human neuronal cells supports the pre-clinical development of a clinical trial using AAV-based NPY for pharmacoresistant epilepsy.
|
29367144 |
2018 |
|
Epilepsy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to compare insulin, leptin, neuropeptide Y and ghrelin levels in children with epilepsy receiving monotherapy with topiramate (TPM) and valproic acid (VPA), the drugs whose effects on body weight have been most discussed, with those of a control group.
|
29679911 |
2018 |
|
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Current evidences suggest that inhibiting BDNF-TrkB signaling and reinforcing the NPY system could represent a potential therapeutic strategy for epilepsy, especially for temporal lobe epilepsy.
|
30262417 |
2018 |
|
Epilepsy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Studies have shown that viral-mediated "gene therapy" with overexpression of NPY in the hippocampus can suppress seizures in acquired epilepsy animal models.
|
29414380 |
2018 |
|
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The reduction of the levels of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 caused by leptin, ghrelin, and NPY shows that these peptides may have anti-inflammatory effects in epileptic seizures.
|
27522536 |
2017 |
|
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several reports have demonstrated that neuropeptide Y (NPY) is involved in food intake, epilepsy, circadian rhythms, drug seeking, pain and anxiety, and other physiological or pathological conditions.
|
29042065 |
2017 |
|
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neuropeptide Y (NPY) is a peptide found in the brain and autonomic nervous system, which is associated with anxiety, depression, epilepsy, learning and memory, sleep, obesity and circadian rhythms.
|
23994577 |
2013 |
|
Epilepsy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Correlating with the seizure disorder are enhanced hippocampal levels of neuropeptide Y and EAAT3 and increased calpain proteolysis of alphaII spectrin.
|
20231455 |
2010 |
|
Epilepsy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Furthermore, was also investigated the mRNA expression of neuropeptide Y, a considered antiepileptic neuropeptide, in the pilocarpine-induced epilepsy.
|
20064661 |
2010 |
|
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results establish a proof-of-principle for the applicability of AAV-NPY vectors for the inhibition of seizures in epilepsy.
|
17196301 |
2007 |
|
Epilepsy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we investigated whether similar changes in the NPY system may also take place in human epilepsy.
|
11466452 |
2001 |
|
Epilepsy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
NPY in a dose of 2 mg (470 pmol), but not 1 mg, inhibited some excitatory effects of picrotoxin, but did not change the epileptic symptoms.
|
8868293 |
1996 |